A harm-reduction look at survodutide, an investigational GLP-1/glucagon agonist with obesity and MASH data, not yet approved.
At a glance
Best for
Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim for obesity and for MASH (metabolic dysfunction-associated steatohepatitis). The GLP-1 arm reduces appetite while the glucagon arm targets liver fat and energy expenditure. In the Phase 3 SYNCHRONIZE-1 obesity trial, survodutide produced up to about 16.6 percent mean weight loss at 76 weeks versus 3.2 percent for placebo, and it has generated strong liver data, including the LIVERAGE MASH program and a Breakthrough Therapy designation.
Survodutide is investigational and not approved. This is an educational tracking guide, not medical advice or a recommendation.
In the SYNCHRONIZE trials, survodutide is titrated upward over weeks to a maintenance dose to limit GI intolerance, given once weekly by subcutaneous injection. Doses cited anywhere reflect the trial protocol only, not a personal target.
The obesity and liver data are promising but come from trials, not real-world use. Titration matters for tolerability, and weight loss is gradual. As with any rapid loss, some can be lean mass, so protein and resistance training belong in the tracking sheet.
Survodutide is not approved and its full risk profile is still being defined. Expect GLP-1 class GI effects and heart-rate changes, and note that glucagon agonism adds metabolic effects worth monitoring. Anyone using it outside a trial is outside the evidence base and should be under medical supervision.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.